--News Direct--
Context Therapeutics CEO Marty Lehr joins Natalie Stoberman from the Proactive studios to discuss the latest data on clinical cancer target Claudin 6 (CLDN6) presented at ASCO23 and how Context’s CTIM-76 CLDN6 X CD3 bispecific antibody sets itself apart from other CLDN6-targeted clinical candidates.
Lehr says CLDN6 is differentially expressed on cancer cells with no or very low expression in normal, healthy adult tissue. CLDN6-enriched cancers include non-small cell lung (NSCLC), ovarian, testicular, and others.
CTIM-76 is currently in preclinical development and is intended to direct activated immune T cells to CLDN6-expressing cancer cells. Preclinical studies of evaluating CTIM-76 demonstrates selective immune-mediated cell death of CLDN6-positive cancer cells.
Contact DetailsProactive Investors USA
+1 347-449-0879
na-editorial@proactiveinvestors.com
View source version on newsdirect.com: https://newsdirect.com/news/context-therapeutics-shares-asco23-data-on-cldn-6-targeted-treatments-and-ctim-76-update-305352892
